XRTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XR

Mkt Cap

$2.3M

Volume

89.25K

Next Earnings

November 13th

Loading chart

XR

XRTXXORTX Therapeutics Inc. Common Stock

XRTX

Pay with—

Available Balance0.00

XR

Mkt Cap

$2.3M

Volume

89.25K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

XORTX Announces Termination and Postponement of Investor Relations ProgramXORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.GlobeNewswire Inc. · Aug 28, 2026

XORTX Announces Election to Voluntary Delist from the TSX Venture ExchangeXORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing its XRx-026 gout treatment program. Canadian shareholders will retain full trading access on Nasdaq.GlobeNewswire Inc. · Jun 12, 2026

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic AssetXORTX Therapeutics has completed its acquisition of the VB4-P5 program from Vectus Biosystems, a novel therapeutic targeting kidney fibrosis in chronic kidney disease. The deal valued at US$3.0 million includes patent rights and preclinical data. VB4-P5 is positioned to address a significant unmet medical need in both rare and prevalent kidney diseases affecting millions globally.GlobeNewswire Inc. · Apr 13, 2026

XORTX Confirms Effective Date of Share ConsolidationXORTX Therapeutics announced that its 1-for-5 share consolidation has received all required approvals from TSX Venture Exchange and Nasdaq Stock Exchange, effective April 6, 2026. The company is a late-stage clinical pharmaceutical firm developing therapies for gout and progressive kidney disease, with three clinically advanced products in development.GlobeNewswire Inc. · Apr 1, 2026

XORTX Announces Results of Annual and Special Meeting of ShareholdersXORTX Therapeutics Inc. held its annual and special shareholder meeting on March 24, 2026, with 35% shareholder representation. All proposed matters were approved, including the election of five board members (Anthony Giovinazzo as Chair, Allen Davidoff as CEO, Mika Grasso, Richard Grieve, and George Scorsis), appointment of Davidson & Company LLP as auditors, re-approval of the stock option plan, and approval of a share consolidation.GlobeNewswire Inc. · Mar 26, 2026

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General MeetingXORTX Therapeutics Inc. announced shareholder approval for a 5-to-1 share consolidation to maintain compliance with NASDAQ's listing requirements, specifically ensuring shares trade above $1.00. The consolidation will reduce outstanding shares from approximately 6.96 million to 1.39 million and is pending TSX Venture Exchange approval. The company must achieve the $1.00 threshold by April 13, 2026.GlobeNewswire Inc. · Mar 24, 2026

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share ConsolidationXORTX Therapeutics announced that independent proxy advisory firm ISS has recommended shareholders vote in favor of the company's proposed share consolidation at the March 24, 2026 shareholder meeting. ISS stated the consolidation should have no direct negative impact on shareholder value and could enhance long-term growth prospects by broadening financing alternatives. The proxy voting deadline is March 20, 2026.GlobeNewswire Inc. · Mar 13, 2026

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus BiosystemsXORTX Therapeutics has extended the deadline to complete its acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program (VB4-P5) to March 31, 2026, allowing additional time for intellectual property transfer. The company also announced its Annual and Special Meeting of Shareholders scheduled for March 24, 2026, and granted stock options to new board member Krysta Davies Foss.GlobeNewswire Inc. · Feb 4, 2026

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate UpdateXORTX Therapeutics announced peer-reviewed research linking genetic factors to xanthine oxidase over-expression in gout and kidney disease, supporting the company's therapeutic approach. The company appointed Krysta Davies Foss to its board, corrected warrant issuance numbers from a recent $1.1M offering, and provided updates on its pending acquisition of Vectus Biosystems' renal anti-fibrotic program, expected to close by January 13, 2026.GlobeNewswire Inc. · Dec 31, 2025

XORTX Announces Pricing of US$1.1 Million Registered Direct OfferingXORTX Therapeutics has entered into a securities purchase agreement to sell 1,746,631 common shares at $0.63 per share, expecting to raise approximately $1.1 million for working capital and general corporate purposes.GlobeNewswire Inc. · Oct 21, 2025

to start trading

XR

XRTXXORTX Therapeutics Inc. Common Stock

XRTX

Pay with—

Available Balance0.00

Your PositionYou don't own any XRTX yet.

Related Tickers

Earnings